SBP-1750
SBP-1750 is an orally active ULK inhibitor and an ATG13 degrader. SBP-1750 strongly inhibits ULK1/2 activity, with IC50 values of 8 and 50 nM, respectively. SBP-1750 induces ATG13 degradation, with an EC50 value of 114 nM. SBP-1750 can inhibit autophagy in cancer cells and induce cell death. SBP-1750 can be used in cancer research, such as for pancreatic cancer[1].
Product Specifications
CAS Number
[1884219-70-8]
UNSPSC
12352005
Target
ULK
Related Pathways
Autophagy
Applications
Cancer-programmed cell death
Field of Research
Cancer
Purity
98.05
Smiles
O=C(NC)C1=CC=CC=C1NC2=NC(NC3=CC(OC)=C(OC)C(OC)=C3)=NC=C2Cl
Molecular Formula
C21H22ClN5O4
Molecular Weight
443.88
References & Citations
[1]Hagan PM, et al. ULK1/2 Inhibitors that Degrade ATG13 Effectively Target KRAS-Mutant Cancers. bioRxiv [Preprint]. 2025 Oct 15:2025.10.14.682402.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
ULK1; ULK2
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
Lentiviral human ERCC6L2 shRNA (UAS) - Lentiviral human ERCC6L2 shRNA (UAS, GFP) (25)
